you are viewing a single comment's thread.
Zip... They did not guide sales down. They just said the current quarter contained inventory stock. Sandoz will likely do $250-300M of mLovenox revenue in Q4 2010 and as a result MNTA will earn $1.00-1.30 in EPS in Q4 2010.
down, up, even...All of it should mean we trade much much higher than current levels. It will be interesting what questions analysts will ask on TEVA's call tomorrow.
Then I do not know how to listen.:-)
>>Zip... They did not guide sales down.From the CC:"Sandoz commented that the first launch quarter sales included a significant level of in stocking. So they've suggested that the fourth-quarter enoxaparin sales would be lower than sales for Q3."Sounds like lower guiding to me.:-)